Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.

63 found a highly significant correlation between the probability of major molecular response at 6 years, and the adherence rate (< or = 90% or > 90%) in subjects who had achieved a CCyR on imatinib therapy.

also in 132,142 other papers